文献速递临床试验与 GCP基础与转化研究

裸盖菇素辅助团体心理治疗与正念减压疗法用于一线医护人员COVID-19相关抑郁与职业倦怠:一项随机对照试验

Psilocybin-assisted group psychotherapy and mindfulness-based stress reduction for frontline healthcare provider COVID-19-related depression and burnout: A randomized controlled trial.
PubMed 文献 · PLoS Med · 2025-09-19

本研究为随机对照试验,纳入新冠疫情期间一线工作的医生和护士,比较8周正念减压(MBSR)联合裸盖菇素辅助团体心理治疗(PAP,25 mg裸盖菇素)与单用MBSR的疗效与安全性。主要疗效终点为干预后2周QIDS-SR-16评分变化,联合组较单用MBSR组下降显著更大(组间效应=4.6,95%CI [1.51, 7.70],p=0.008),6个月随访时该效应减弱。未发生严重不良事件,作者认为联合方案可能是有前景的治疗,但需更大样本试验验证。

要点

  • MBSR+PAP组干预后2周QIDS-SR-16评分较单用MBSR组显著下降更多(组间效应=4.6,95%CI [1.51, 7.70],p=0.008)。
  • 记录到12例研究相关1-2级不良事件,无严重不良事件。
  • 6个月随访时抑郁症状改善效应减弱,次要结局经多重比较校正后未达显著。

核心结论

  • 本试验达到主要终点:团体裸盖菇素辅助治疗联合MBSR与抑郁症状的临床显著改善相关,无严重不良事件,且症状下降幅度大于单用MBSR。
  • 作者认为将裸盖菇素与正念训练整合可能代表对医生和护士抑郁与职业倦怠有前景的治疗,但需更大规模试验确立疗效、可推广性和效应持久性。

研究设计与样本

  • 随机对照试验,纳入新冠疫情期间从事一线临床工作的医生和护士,伴抑郁与职业倦怠症状(ClinicalTrials.gov标识:NCT05557643)。
  • 参与者于2023年1月2日至2024年1月16日入组,按1:1随机分配至8周MBSR课程单用组或8周MBSR课程联合团体裸盖菇素辅助心理治疗(PAP,25 mg裸盖菇素)组。
  • 安全性与入组及保留可行性为主要目标之一,主要疗效终点为干预后2周QIDS-SR-16评分的抑郁症状变化。
  • 共25名参与者入组并随机化。

主要发现

  • 线性混合模型分析显示,从基线至干预后2周,MBSR+PAP组QIDS-SR-16评分下降显著大于单用MBSR组(组间效应=4.6,95%CI [1.51, 7.70],p=0.008)。
  • 该效应在6个月随访时减弱。
  • 职业倦怠(MBI-HSS-MP各分量表)、士气低落(DS-II)和连通感(WCS)等次要结局倾向于MBSR+PAP组,但经多重比较校正后未达显著。
  • 记录到12例研究相关1-2级不良事件,无严重不良事件;通过6个月随访评估不良事件和自杀倾向。

临床怎么用

  • 作者认为,将裸盖菇素与正念训练整合可能代表对医生和护士抑郁与职业倦怠有前景的治疗。
  • 作者指出需更大规模试验确立疗效、可推广性和效应持久性。

局限性

  • 样本量小。
  • 研究人群同质。
  • 干预强度存在显著差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Depression and burnout, which are common among healthcare workers, were exacerbated by the COVID-19 pandemic. Mindfulness-Based Stress Reduction (MBSR) and psilocybin have been reported to reduce depressive symptoms, but the efficacy of the combination requires comparison to an active treatment control. We sought to evaluate the safety and preliminary efficacy of psilocybin and MBSR versus MBSR alone for frontline healthcare providers with symptoms of depression and burnout related to the COVID-19 pandemic. We hypothesized that psilocybin would augment the antidepressant effects of MBSR in this population. METHODS AND FINDINGS: We conducted a randomized controlled trial that enrolled physicians and nurses with frontline clinical work during the COVID-19 pandemic and symptoms of depression and burnout. (ClinicalTrials.gov Identifier: NCT05557643) Participants were enrolled between January 2nd, 2023 and January 16th, 2024, and randomized in a 1:1 ratio to either an 8-week MBSR curriculum alone or an 8-week MBSR curriculum plus group psilocybin-assisted psychotherapy (PAP) with 25 mg psilocybin. Evaluation of safety and feasibility of enrollment and retention was a primary objective of the study. The primary efficacy endpoint was change in depressive symptoms, as measured by the Quick Inventory of Depressive Symptoms (QIDS-SR-16) at 2 weeks post-intervention. Symptoms of depression and burnout were assessed at baseline, and 2 weeks and 6 months post-intervention utilizing the Quick Inventory of Depressive Symptoms (QIDS-SR-16) and Maslach Burnout Inventory Human Services Survey for Medical Professionals (MBI-HSS-MP), respectively. Secondary outcome measures included the Demoralization Scale (DS-II) and the Watt's Connectedness Scale (WCS). Adverse events (AEs) and suicidality were assessed through a 6-month follow-up. Twenty-five participants were enrolled and randomized. Safety was a study outcome and assessed by rate and severity of AEs and any incident suicidality or significant mental health symptoms. Baseline and outcome data were summarized using descriptive statistics, with continuous variables reported as means and standard deviations. We recorded 12 study-related, Grade 1-2 AEs and no serious AEs. In a linear mixed model analysis (LMM), the MBSR + PAP arm evidenced a significantly larger decrease in QIDS-SR-16 score than the MBSR-only arm from baseline to 2-weeks post-intervention (between-groups effect = 4.6, 95% CI [1.51, 7.70]; p = 0.008). This effect waned at the 6-month follow-up. Secondary outcome measures for burnout (subscales of the MBI-HSS-MP), demoralization (DS II), and connectedness (WCS) favored the MBSR + PAP arm; however, these effects did not survive correction for multiple comparisons. A mixed RM-ANCOVA was conducted to control for baseline differences in outcome measures. Sensitivity analyses were conducted, adjusting for baseline differences in gender and clustering within group cohorts. Study limitations that affect the generalizability of results include a small sample size, homogenous study population, and significant differences in intervention intensity. CONCLUSIONS: This trial met its primary endpoint: group psilocybin-assisted therapy plus MBSR was associated with clinically significant improvement in depressive symptoms without serious AEs and with greater reduction in symptoms than MBSR alone. Our findings suggest that integrating psilocybin with mindfulness training may represent a promising treatment for depression and burnout among physicians and nurses. Larger trials are needed to establish efficacy, generalizability, and durability of these effects.

来源:PLoS Med,查看原文。版权归原作者所有。

引用

  1. Lewis BR, Hendrick J, Byrne K, et al. Psilocybin-assisted group psychotherapy and mindfulness-based stress reduction for frontline healthcare provider COVID-19-related depression and burnout: A randomized controlled trial. PLoS Med. 2025. PMID: 40972137. doi:10.1371/journal.pmed.1004519

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。